Uday Khire, PhD MBA
Co-founder, Chief Executive Officer
Dr. Khire is a scientist and an entrepreneur with international business experience. Dr. Khire co-founded AlloMek Therapeutics
in 2011 based on discovery of novel macrocyclic MEK kinase inhibitor at Cheminpharma LLC, a drug discovery services
company, founded by him. Prior to founding Cheminpharma in 2007, Dr. Khire worked as a senior scientist at Bayer Research
Center. He played a key part in the discovery of “Nexavar”, a first in class B-Raf kinase inhibitor (MAP/ERK pathway) which has
been approved as a first line therapy for a treatment of kidney and liver cancers. Dr. Khire did
post-doctoral research at Purdue University under guidance of Late Prof. H. C. Brown, a Nobel laureate in chemistry. Dr. Khire
did another postdoctoral research at University of California, Irvine, where he worked on total synthesis of challenging
molecule, roflamycin, a polyol polyene macrocycle, wherein, he developed interest in macrocycles.
Prior to his post-doctoral position Dr. Khire received his PhD from National Chemical laboratory in India. Dr. Khire earned his
MBA from New Jearsey based Fairleigh Dickinson University. Dr. Khire is fascinated by macrocycles and potential of these large
cyclic compounds in various therapeutics areas.